Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management.
Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management.
复制标题
严重的COVID-19，儿童的多系统炎症综合征和川崎疾病：免疫机制，临床表现和管理。
DOI：
10.1007/s00296-020-04749-4
复制
发表时间：
2021-01
影响因子：
4
通讯作者：
Singh S
中科院分区：
文献类型：
--
作者：
Kabeerdoss J;Pilania RK;Karkhele R;Kumar TS;Danda D;Singh S
多系统炎性综合征（MIS-C）是由严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）引起的儿科炎症性疾病。现在全世界有几个国家都有报道。MIS-C型酷似川崎休克综合征的部分临床表现MIS-C在SARS-CoV-2感染后4-6周发展，并且推测是由适应性免疫应答启动的。虽然它有多系统的参与，它是最突出的心血管表现。在这些患者中观察到高滴度的抗SARS-CoV-2抗体。由于这是一种新的疾病实体，其免疫发病机制尚未完全阐明。它是否与KD有一些重叠尚不清楚。目前的治疗指南推荐使用静脉注射免疫球蛋白和大剂量皮质类固醇作为一线治疗。MIS-C的死亡率低于成人形式的严重COVID-19疾病。本文的在线版本（10.1007/s 00296 -020-04749-4）包含补充材料，可供授权用户使用。
Multisystem inflammatory syndrome (MIS-C) is a pediatric hyperinflammation disorder caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It has now been reported from several countries the world over. Some of the clinical manifestations of MIS-C mimic Kawasaki disease (KD) shock syndrome. MIS-C develops 4–6 weeks following SARS-CoV-2 infection, and is presumably initiated by adaptive immune response. Though it has multisystem involvement, it is the cardiovascular manifestations that are most prominent. High titres of anti-SARS-CoV-2 antibodies are seen in these patients. As this is a new disease entity, its immunopathogenesis is not fully elucidated. Whether it has some overlap with KD is still unclear. Current treatment guidelines recommend use of intravenous immunoglobulin and high-dose corticosteroids as first-line treatment. Mortality rates of MIS-C are lower compared to adult forms of severe COVID-19 disease. The online version of this article (10.1007/s00296-020-04749-4) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
36.4
作者：
Davies, Patrick;Evans, Claire;Ramnarayan, Padmanabhan
通讯作者：
Ramnarayan, Padmanabhan
影响因子：
11.8
作者：
Chiu, SS;Chan, KH;Peiris, JSM
通讯作者：
Peiris, JSM
影响因子：
2.3
作者：
Bhat CS;Gupta L;Balasubramanian S;Singh S;Ramanan AV
通讯作者：
Ramanan AV
影响因子：
6.4
作者：
Dominguez, Samuel R.;Anderson, Marsha S.;Holmes, Kathryn V.
通讯作者：
Holmes, Kathryn V.
影响因子：
6.8
作者：
Chen, Juan;Zhang, Zhen-Zhen;Huang, Ai-Long
通讯作者：
Huang, Ai-Long